rxstat › Shortages › Efavirenz Tenofovir Disoproxil Emtricitabine

Efavirenz Tenofovir Disoproxil Emtricitabine shortage status

Partial shortage

Source: Health Canada shortage reports · Updated Jul 9, 2026

Some Efavirenz Tenofovir Disoproxil Emtricitabine products are in shortage in Canada (3 of 7 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Dec 31, 2026.
Products affected
3 / 7
In shortage since
Oct 7, 2024
Est. full return
Dec 31, 2026
Reports on file
16
Talk to your pharmacist. Pharmacists can often substitute another manufacturer's version, a different strength, or (in most provinces) adapt or renew a prescription on the spot. Your free provincial health line is 811.

Reports by product

Active shortage
JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE
600MG 300MG 200MG · TABLET · JAMP PHARMA CORPORATION
DIN 02519461 · since Mar 12, 2026, est. end Dec 31, 2026 · Disruption of the manufacture of the drug.
Active shortage
MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE
300MG 200MG 600MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02461412 · since Oct 7, 2024, no end estimate · Disruption of the manufacture of the drug.
Active shortage
TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR
300MG 200MG 600MG · TABLET · TEVA CANADA LIMITED
DIN 02393549 · since Jan 20, 2025, no end estimate · Disruption of the manufacture of the drug.
Resolved
AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
300MG 200MG 600MG · TABLET · AURO PHARMA INC
DIN 02478404 · ended Dec 2, 2024 · Demand increase for the drug.
Resolved
APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
300MG 200MG 600MG · TABLET · APOTEX INC
DIN 02468247 · ended Sep 5, 2024 · Disruption of the manufacture of the drug.
Resolved
AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
300MG 200MG 600MG · TABLET · AURO PHARMA INC
DIN 02478404 · ended Nov 1, 2023 · Demand increase for the drug.
Resolved
APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
300MG 200MG 600MG · TABLET · APOTEX INC
DIN 02468247 · ended Jul 4, 2023 · Disruption of the manufacture of the drug.
Resolved
TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR
300MG 200MG 600MG · TABLET · TEVA CANADA LIMITED
DIN 02393549 · ended Feb 10, 2023 · Disruption of the manufacture of the drug.
Resolved
PMS-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
600MG 300MG 200MG · TABLET · PHARMASCIENCE INC
DIN 02487284 · ended Oct 21, 2022 · Disruption of the manufacture of the drug.
Discontinued
ATRIPLA
300MG 200MG 600MG · TABLET · GILEAD SCIENCES, LLC
DIN 02300699
Resolved
AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
600MG 200MG 300MG · TABLET · AURO PHARMA INC
DIN 02478404 · ended May 25, 2021 · Demand increase for the drug.
Avoided
AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
600MG 200MG 300MG · TABLET · AURO PHARMA INC
DIN 02478404 · ended Mar 26, 2020 · Demand increase for the drug.

Showing 12 of 16 reports. All reports are on file with Health Canada.

What's happening

Efavirenz Tenofovir Disoproxil Emtricitabine is currently affected by 3 active shortage reports filed with Health Canada by JAMP PHARMA CORPORATION, MYLAN PHARMACEUTICALS ULC, TEVA CANADA LIMITED.

The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Efavirenz Tenofovir Disoproxil Emtricitabine is classified under “DIRECT ACTING ANTIVIRALS” (ATC J05AR).

Recent changes

Common questions

When will Efavirenz Tenofovir Disoproxil Emtricitabine be back in stock in Canada?

The latest manufacturer estimate is Dec 31, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.

Why is Efavirenz Tenofovir Disoproxil Emtricitabine in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Related drugs (direct acting antivirals)

Partial shortageAdefovir Dipivoxil1 of 2 reported products affectedPartial shortageAtazanavir3 of 8 reported products affectedPartial shortageDarunavir2 of 9 reported products affected · est. return Jul 24, 2026Partial shortageEfavirenz1 of 6 reported products affectedPartial shortageEntecavir2 of 5 reported products affected · est. return Aug 7, 2026Partial shortageFamciclovir3 of 17 reported products affected

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.